{"id":"mva-bn-vaccine","safety":{"commonSideEffects":[{"rate":"48-70","effect":"Injection site reactions (erythema, swelling, pain)"},{"rate":"30-40","effect":"Myalgia"},{"rate":"25-35","effect":"Fatigue"},{"rate":"20-30","effect":"Headache"},{"rate":"10-20","effect":"Fever"},{"rate":"5-15","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MVA-BN (modified vaccinia Ankara-Bavarian Nordic) is a replication-competent orthopoxvirus vaccine derived from vaccinia virus. It expresses immunogenic proteins from monkeypox virus, triggering both cellular and humoral immune responses. The vaccine primes T-cell and B-cell immunity to provide protection against mpox infection and disease.","oneSentence":"MVA-BN is a live attenuated vaccinia virus vaccine that stimulates immune responses against monkeypox virus antigens to provide protection against mpox infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:56:11.025Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of mpox (monkeypox) infection in adults at risk of exposure"},{"name":"Post-exposure prophylaxis for mpox"}]},"trialDetails":[{"nctId":"NCT05740982","phase":"PHASE2","title":"A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-03-22","conditions":"Monkeypox","enrollment":450},{"nctId":"NCT05734508","phase":"PHASE4","title":"Assessment of Safety Profile of MVA-BN Vaccine in the PALM-007 Study in DRC","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-03-23","conditions":"Monkeypox","enrollment":500},{"nctId":"NCT02743455","phase":"PHASE1","title":"A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-07-05","conditions":"Yellow Fever, Yellow Fever Immunisation","enrollment":92},{"nctId":"NCT06844500","phase":"PHASE3","title":"Phase 3 Maternal Safety & Immunogenicity Trial of MVA-BN® in DRC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jean-Pierre Van geertruyden","startDate":"2025-06-23","conditions":"Neonate, Maternal Transmission, Mpox","enrollment":359},{"nctId":"NCT04983030","phase":"PHASE1, PHASE2","title":"Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boris Juelg, MD PhD","startDate":"2022-04-01","conditions":"HIV, Acquired Immunodeficiency Syndrome, Immunologic Deficiency Syndrome, Acquired","enrollment":36},{"nctId":"NCT07253675","phase":"PHASE2","title":"Evaluate the Safety and Immunogenicity of the MVA-SIBP Vaccine in the Democratic Republic of the Congo","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Institute Of Biological Products","startDate":"2025-12-31","conditions":"Monkeypox (Mpox)","enrollment":180},{"nctId":"NCT06549530","phase":"PHASE2","title":"Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bavarian Nordic","startDate":"2024-10-21","conditions":"Monkeypox (Mpox)","enrollment":460},{"nctId":"NCT07199569","phase":"PHASE2","title":"Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells","status":"RECRUITING","sponsor":"Bavarian Nordic","startDate":"2025-10-27","conditions":"Monkeypox (Mpox)","enrollment":744},{"nctId":"NCT06366672","phase":"EARLY_PHASE1","title":"Evaluating the Human Immune Response to the JYNNEOS Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-06-10","conditions":"Vaccinia, Virus Diseases","enrollment":20},{"nctId":"NCT06899802","phase":"PHASE2","title":"A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bavarian Nordic","startDate":"2025-03-10","conditions":"Encephalitis","enrollment":411},{"nctId":"NCT03493945","phase":"PHASE1, PHASE2","title":"Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-05-01","conditions":"Metastatic Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Neoplasm","enrollment":59},{"nctId":"NCT06844487","phase":"PHASE3","title":"Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRC","status":"RECRUITING","sponsor":"Jean-Pierre Van geertruyden","startDate":"2025-05-29","conditions":"Mpox (Monkeypox), Vaccination, Immunogenicity","enrollment":344},{"nctId":"NCT06839989","phase":"PHASE2","title":"An Immunogenicity and Safety Trial of MVA-BN in Adults Living With HIV for the Prevention of Mpox Infection, in Kinshasa, DRC","status":"RECRUITING","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2025-08-04","conditions":"Mpox (Monkeypox)","enrollment":600},{"nctId":"NCT02891980","phase":"PHASE1","title":"A Safety Trial to Test MVA-BN(R)-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-03-24","conditions":"Ebola Disease, Marburg Disease","enrollment":65},{"nctId":"NCT03583606","phase":"PHASE1","title":"A Trial to Evaluate the Safety and Systems Biology Response of Ebolavirus Zaire Vaccine (ChAd3-EBO-Z)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-11-12","conditions":"Ebola Disease, Immunisation","enrollment":61},{"nctId":"NCT03547999","phase":"PHASE2","title":"A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC","status":"TERMINATED","sponsor":"Patrick Boland","startDate":"2018-06-26","conditions":"Metastatic Colorectal Cancer","enrollment":17},{"nctId":"NCT02543268","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2015-09-21","conditions":"Healthy","enrollment":329},{"nctId":"NCT04228783","phase":"PHASE3","title":"A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2020-02-18","conditions":"Ebola","enrollment":974},{"nctId":"NCT03929757","phase":"PHASE2","title":"A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2019-08-19","conditions":"Ebola Virus Disease","enrollment":108},{"nctId":"NCT02543567","phase":"PHASE3","title":"A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2015-09-21","conditions":"Healthy","enrollment":525},{"nctId":"NCT06885853","phase":"","title":"Evaluation of Long-term Immunogenicity of a Boost Dose of MVA-BN Vaccine","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-05-07","conditions":"Monkeypox","enrollment":90},{"nctId":"NCT05284097","phase":"PHASE2","title":"Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2022-09-19","conditions":"Virus Diseases, Hemorrhagic Fever, Ebola, Infections","enrollment":133},{"nctId":"NCT04491955","phase":"PHASE2","title":"Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2020-09-22","conditions":"Small Bowel Cancers, Colorectal Cancers","enrollment":32},{"nctId":"NCT02977715","phase":"PHASE3","title":"JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the Democratic Republic of the Congo","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centers for Disease Control and Prevention","startDate":"2017-02-23","conditions":"Monkeypox Virus Infection","enrollment":1600},{"nctId":"NCT05512949","phase":"PHASE2","title":"Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-09-09","conditions":"Monkeypox","enrollment":229},{"nctId":"NCT02598388","phase":"PHASE2","title":"Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2015-12-10","conditions":"Hemorrhagic Fever, Ebola","enrollment":578},{"nctId":"NCT04574583","phase":"PHASE1, PHASE2","title":"Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta \"Trap\"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2020-11-24","conditions":"Metastatic Cancer, Solid Tumors","enrollment":12},{"nctId":"NCT04556526","phase":"PHASE3","title":"A Study of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant Women","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2020-10-05","conditions":"Healthy","enrollment":4031},{"nctId":"NCT05238025","phase":"PHASE3","title":"MVA-BN-RSV Vaccine Trial","status":"TERMINATED","sponsor":"Bavarian Nordic","startDate":"2022-04-19","conditions":"Respiratory Syncytial Virus Infections","enrollment":20419},{"nctId":"NCT02876328","phase":"PHASE2","title":"Partnership for Research on Ebola VACcinations","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-03-27","conditions":"Ebola Virus Disease","enrollment":4789},{"nctId":"NCT05769569","phase":"PHASE1","title":"Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission","status":"WITHDRAWN","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2023-09-01","conditions":"HIV-1-infection","enrollment":""},{"nctId":"NCT05445882","phase":"PHASE2","title":"N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-01","conditions":"Castration Resistant Prostate Cancer","enrollment":""},{"nctId":"NCT04410874","phase":"PHASE1, PHASE2","title":"Imvamune Vaccine for the Treatment of Non-melanoma Skin Cancer","status":"TERMINATED","sponsor":"Ivan Litvinov","startDate":"2020-11-16","conditions":"Non-melanoma Skin Cancer, Basal Cell Carcinoma, Squamous Cell Carcinoma","enrollment":1},{"nctId":"NCT02661464","phase":"PHASE3","title":"Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo","status":"TERMINATED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2016-05-31","conditions":"Hemorrhagic Fever, Ebola","enrollment":677},{"nctId":"NCT04711356","phase":"PHASE2","title":"Ad26.ZEBOV Booster in Children Previously Vaccinated With Ad26.ZEBOV and MVA-BN-Filo (EBOVAC Booster Study)","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2021-07-08","conditions":"Ebola Virus Disease","enrollment":50},{"nctId":"NCT04752644","phase":"PHASE2","title":"Phase 2a Study of MVA-BN-RSV Vaccination and RSV Challenge in Healthy Adults","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2021-02-22","conditions":"RSV Infection","enrollment":73},{"nctId":"NCT05064956","phase":"PHASE2","title":"Ad26.ZEBOV Booster in HIV+ Adults Previously Vaccinated With Ad26.ZEBOV/MVA-BN-Filo (EBOVAC HIV+ Booster Study)","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2021-10-06","conditions":"Ebola Virus Disease, Ebola, Hiv","enrollment":26},{"nctId":"NCT03820739","phase":"","title":"EBOVAC-Salone Extension","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2019-07-22","conditions":"Ebola Virus Disease","enrollment":653},{"nctId":"NCT04186000","phase":"PHASE2","title":"Study to Evaluate the Immunogenicity and Safety of a Heterologous Vaccine Regimen Against Ebola","status":"COMPLETED","sponsor":"Universiteit Antwerpen","startDate":"2019-12-18","conditions":"Ebola Virus Disease","enrollment":699},{"nctId":"NCT02509494","phase":"PHASE3","title":"Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2015-09-30","conditions":"Ebola Virus Disease","enrollment":1023},{"nctId":"NCT02564523","phase":"PHASE2","title":"Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2015-11-06","conditions":"Hemorrhagic Fever, Ebola","enrollment":1075},{"nctId":"NCT04296942","phase":"PHASE1","title":"BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-04","conditions":"Breast Cancer, Triple Negative Breast Cancer, HER2+ Breast Cancer","enrollment":1},{"nctId":"NCT04152486","phase":"PHASE3","title":"Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC","status":"UNKNOWN","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2019-11-14","conditions":"Ebola Virus Disease","enrollment":20426},{"nctId":"NCT04134312","phase":"PHASE1","title":"A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2020-01-08","conditions":"Solid Metastatic Tumor","enrollment":13},{"nctId":"NCT03699124","phase":"PHASE3","title":"Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2019-06-19","conditions":"Smallpox","enrollment":1129},{"nctId":"NCT04028349","phase":"PHASE2","title":"ZEBOVAC (Ebola Vaccine Trial, Ad26.ZEBOV/MVA-BN-Filo)","status":"COMPLETED","sponsor":"MRC/UVRI and LSHTM Uganda Research Unit","startDate":"2019-08-01","conditions":"Ebola Virus Disease","enrollment":800},{"nctId":"NCT02416453","phase":"PHASE2","title":"A Study to Assess Safety, Tolerability, and Immunogenicity of Three Heterologus 2-dose Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2015-06-15","conditions":"Ebola Viral Disease","enrollment":423},{"nctId":"NCT01668537","phase":"PHASE2","title":"A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2013-03","conditions":"Smallpox","enrollment":651},{"nctId":"NCT02873286","phase":"PHASE2","title":"RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2016-09","conditions":"Respiratory Syncytial Virus Infections","enrollment":420},{"nctId":"NCT03349983","phase":"PHASE1","title":"Safety and Tolerability Trial (MVA-BN-Brachyury/FPV-Brachyury)","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2018-01-08","conditions":"Safety Issues","enrollment":11},{"nctId":"NCT04131595","phase":"PHASE1","title":"Vaccination Trial of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2019-10-07","conditions":"Equine Encephalitis","enrollment":45},{"nctId":"NCT03472014","phase":"PHASE4","title":"Special Access Program IMVAMUNE®","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2010-04-22","conditions":"Vaccination","enrollment":22},{"nctId":"NCT03140774","phase":"","title":"Persistence of the Immune Response After Immunisation With Ebola Virus Vaccines","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2017-05-17","conditions":"Ebola Virus Disease","enrollment":126},{"nctId":"NCT02038881","phase":"PHASE2","title":"Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2014-04-28","conditions":"Smallpox","enrollment":87},{"nctId":"NCT03745131","phase":"","title":"Cohort Study of Healthcare Workers Receiving Imvanex®","status":"COMPLETED","sponsor":"Public Health England","startDate":"2018-10-30","conditions":"Monkeypox","enrollment":120},{"nctId":"NCT01913353","phase":"PHASE3","title":"A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000®","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2015-03","conditions":"18-42 Year Old Healthy Vaccinia-naïve Subjects","enrollment":440},{"nctId":"NCT02267109","phase":"PHASE1","title":"Phase 1 Trial of Ebola Vaccine in Mali","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2014-10","conditions":"Ebola Virus Disease, Hemorrhagic Fever","enrollment":91},{"nctId":"NCT00485277","phase":"PHASE1","title":"A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2007-06","conditions":"Breast Cancer","enrollment":9},{"nctId":"NCT01152398","phase":"PHASE1","title":"A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2010-06","conditions":"Breast Cancer","enrollment":15},{"nctId":"NCT00629057","phase":"PHASE1","title":"A Safety Trial of MVA-BN®-PRO in Men With Androgen-Insensitive Prostate Cancer","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2008-03","conditions":"Androgen-insensitive Prostate Cancer","enrollment":24},{"nctId":"NCT00686582","phase":"PHASE2","title":"An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2008-08","conditions":"Smallpox","enrollment":304},{"nctId":"NCT00316524","phase":"PHASE2","title":"A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallpox Vaccine in Healthy Subjects","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2006-04","conditions":"Smallpox","enrollment":745},{"nctId":"NCT00189956","phase":"PHASE2","title":"Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine.","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2003-04","conditions":"Smallpox","enrollment":165},{"nctId":"NCT00189917","phase":"PHASE1","title":"Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic Disorders","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2004-04","conditions":"Dermatitis, Atopic, Hay Fever","enrollment":60},{"nctId":"NCT00316602","phase":"PHASE2","title":"A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2006-07","conditions":"Atopic Dermatitis","enrollment":632},{"nctId":"NCT00316589","phase":"PHASE2","title":"Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2006-06","conditions":"HIV Infections","enrollment":581},{"nctId":"NCT01144637","phase":"PHASE3","title":"A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2013-02","conditions":"Smallpox","enrollment":4005},{"nctId":"NCT02864628","phase":"PHASE1","title":"RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults.","status":"WITHDRAWN","sponsor":"Bavarian Nordic","startDate":"2016-09","conditions":"Respiratory Syncytial Virus Infections","enrollment":""},{"nctId":"NCT02240875","phase":"PHASE1","title":"A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2014-09-17","conditions":"Ebola, Ebola Zaire","enrollment":91},{"nctId":"NCT02860650","phase":"PHASE1","title":"A Study to Evaluate Safety, Tolerability, and Immunogenicity of Heterologous Prime-boost Regimens Using the Multivalent Filovirus Vaccines Ad26.Filo and MVA-BN-Filo Administered in Different Sequences and Schedules in Healthy Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2016-08","conditions":"Healthy","enrollment":72},{"nctId":"NCT02325050","phase":"PHASE1","title":"A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2015-01-08","conditions":"Healthy","enrollment":164},{"nctId":"NCT02313077","phase":"PHASE1","title":"A Safety and Immunogenicity Study of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2014-12-17","conditions":"Healthy","enrollment":87},{"nctId":"NCT02376426","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2015-03","conditions":"Healthy","enrollment":72},{"nctId":"NCT02376400","phase":"PHASE1","title":"A Study to Assess the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2015-04","conditions":"Healthy","enrollment":78},{"nctId":"NCT02419391","phase":"PHASE1","title":"Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2015-08","conditions":"Respiratory Syncytial Virus Infections","enrollment":63},{"nctId":"NCT00082446","phase":"PHASE1","title":"Combination Study With MVA BN and Dryvax","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-05","conditions":"Smallpox","enrollment":91},{"nctId":"NCT00565929","phase":"PHASE1","title":"Safety, Reactogenicity and Immunogenicity of MVA in Hematopoietic Stem Cell Transplant (HSCT) Subjects","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-09","conditions":"Variola Major (Smallpox)","enrollment":24},{"nctId":"NCT00189930","phase":"PHASE2","title":"An Evaluation of Immunogenicity and Safety of Two Doses of MVA-nef vs. MVA-BN in HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2005-04","conditions":"HIV Infection","enrollment":77},{"nctId":"NCT00189904","phase":"PHASE1, PHASE2","title":"Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2005-07","conditions":"HIV Infections","enrollment":151},{"nctId":"NCT00189943","phase":"PHASE1","title":"Study on Safety, Tolerability and Immunogenicity of an MVA Vaccine Administered to Healthy Subjects","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2001-04","conditions":"Smallpox","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":44,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["JYNNEOS"],"phase":"marketed","status":"active","brandName":"MVA-BN vaccine","genericName":"MVA-BN vaccine","companyName":"National Institute of Allergy and Infectious Diseases (NIAID)","companyId":"national-institute-of-allergy-and-infectious-diseases-niaid","modality":"Biologic","firstApprovalDate":"","aiSummary":"MVA-BN is a live attenuated vaccinia virus vaccine that stimulates immune responses against monkeypox virus antigens. Used for Monkeypox (mpox) prevention in adults at risk, Post-exposure prophylaxis for monkeypox.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}